A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference

Journal of Cystic Fibrosis

Volumn 11, Issue 3, 2012, Pages 231-236

  Leonard, Anissa ^a   Lebecque, Patrick ^a   Dingemanse, Jasper ^b   Leal, Teresinha ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Cystic fibrosis; Efficacy; F508del; Miglustat; Pharmacokinetics; Tolerability

Indexed keywords

CHLORIDE; MIGLUSTAT; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEADACHE; HOMOZYGOSITY; HUMAN; HYPERTENSION; INSOMNIA; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

1-DEOXYNOJIRIMYCIN; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALPHA-GLUCOSIDASES; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NASAL MUCOSA; SODIUM CHLORIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860605804     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.12.004     Document Type: Article

References (31)

1. Rommens J.M., Iannuzzi M.C., Kerem B., Drumm ML., Melmer G., Dean M., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
2. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
3. Noel S., Wilke M., Bot A.G., De Jonge H.R., Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008, 325:1016-1023.
4. Actelion Miglustat (Zavesca®) capsules summary of product information Accessed 5 July, 2011. http://eudrapharm.eu/eudrapharm/showDocument?documentId=299255761182430949.
5. Actelion ZAVESCA® [miglustat] package insert Accessed 5 July, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf.
6. Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006, 580:2081-2086.
7. Antigny F., Norez C., Becq F., Vandebrouck C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008, 43:175-183.
8. Lubamba B., Lebacq J., Lebecque P., Vanbever R., Leonard A., Wallemacq P., et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009, 179:1022-1028.
9. Knudson R., Lebowitz M., Holberg C., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
10. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003, 349:1433-1441.
11. Leal T., Lebacq J., Lebecque P., Cumps J., Wallemacq P. Modified method to measure nasal potential difference. Clin Chem Lab Med 2003, 41:61-67.
12. Spieker E., Wagner-Redeker W., Dingemanse J. Validated LC-MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal 2012, 59:123-129.
13. Yaakov Y., Kerem E., Yahav Y., Rivlin J., Blau H., Bentur L., et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007, 132:1219-1226.
14. Rubenstein R.C., Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998, 157:484-490.
15. Wilschanski M., Famini C., Blau H., Rivlin J., Augarten A., Avital A., et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000, 161:860-865.
16. Clancy J.P., Bebök Z., Ruiz F., King C., Jones J., Walker L., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:1683-1692.
17. Sermet-Gaudelus I., Renouil M., Fajac A., Bidou L., Parbaille B., Pierrot S., et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007, 5:5.
18. Clancy J.P., Rowe S.M., Bebok Z., Aitken M.L., Gibson R., Zeitlin P., et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007, 37:57-66.
19. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
20. Sermet-Gaudelus I., De Boeck K.D., Casimir G.J., Vermeulen F., Leal T., Mogenet A., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010, 182:1262-1272.
21. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
22. Wilschanski M., Miller L.L., Shoseyov D., Blau H., Rivlin J., Aviram M., et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011, 38:59-69.
23. Clancy J.P., Rowe S., Accurso F., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis and homozygous for the F508del-CFTR mutation. Thorax Nov 5 2011, [Epub ahead of print].
24. Rowe S.M., Accurso F., Clancy J.P. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007, 4:387-398.
25. Solomon G.M., Konstan M.W., Wilschanski M., Billings J., Sermet-Gaudelus I., Accurso F., et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010, 138. 9129 9128.
26. Lebecque P., Leal T., De Boeck C., Jaspers M., Cuppens H., Cassiman J.J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 2002, 165:757-761.
27. Middleton P.G., House H.H. Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatr Pulmonol 2010, 45:789-795.
28. Wilschanski M., Dupuis A., Ellis L., Jarvi K., Zielenski J., Tullis E., et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potential. Am J Respir Crit Care Med 2006, 174:787-794.
29. Leal T., Fajac I., Wallace H.L., Lebecque P., Lebacq J., Hubert D., et al. Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 2008, 41:764-772.
30. 1 rate of decline in CF patients: towards zero over a 8 year period. J Cyst Fibros 2009, 8:S2-S61. (A).
31. Welsh M.J. Targeting the basic defect in cystic fibrosis. N Engl J Med 2010, 363:2056-2057.